30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Cerapedics Closes $11 Million Series D Financing -

Cerapedics completed a US $11MM Series D financing. Funds will support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft, which received FDA premarket approval in 4Q15 for use in anterior cervical discectomy and fusion (ACDF) to treat degenerative disc disease. Proceeds will also further development of synthetic small peptide technology (P-15) for lumbar spinal fusion.

The 4Q15 PMA for i-FACTOR represented the first approval of bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine (the first being INFUSE). 

Sources: Cerapedics; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.